Acute infectious pediatric gastroenteritis: Beyond oral rehydration therapy

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1651-1665

  Freedman, Stephen B ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bismuth subsalicylate; Diarrhea; Gastroenteritis; Loperamide; Nitazoxanide; Ondansetron; Probiotics; Racecadotril; Rapid intravenous rehydration; Rotavirus; Vaccine; Vomiting; Zinc

Indexed keywords

ACETORPHAN; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; BENZAMIDE DERIVATIVE; BISMUTH SALICYLATE; BUTYROPHENONE DERIVATIVE; CHOLERA VACCINE; COLORVAC; DIOCTAHEDRAL SMECTITE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; HIDRASEC; LIVE VACCINE; LOPERAMIDE; MAGNESIUM SALICYLATE; METOCLOPRAMIDE; MUTACOL; NITAZOXANIDE; ONDANSETRON; PLACEBO; PROBIOTIC AGENT; PROCHLORPERAZINE; PROMETHAZINE; ROTAVIRUS VACCINE; SEROTONIN ANTAGONIST; STOMACH SECRETION INHIBITOR; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG; ZINC;

ACUTE GASTROENTERITIS; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CHOLERA; CLINICAL TRIAL; CONSTIPATION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DRUG APPROVAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FOLLOW UP; HUMAN; HYPOKALEMIA; ILEUS; INFECTION; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORAL REHYDRATION THERAPY; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; CHILD; CHILD, PRESCHOOL; FLUID THERAPY; GASTROENTERITIS; HUMANS; ROTAVIRUS VACCINES;

EID: 34548137764     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1651     Document Type: Review

References (162)

1. KOSEK M, BERN C, GUERRANT RL: The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ. (2003) 81(3):197-204.
2. UNICEF: The state of the world's children. Oxford University Press, Oxford, UK (1998).
3. SNYDER JD, MERSON MH: The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull. World Health. Organ. (1982) 60(4):605-613.
4. SANTOSHAM M: Oral rehydration therapy: reverse transfer of technology. Arch. Pediatr. Adolesc. Med. (2002) 156(12):1177-1179.
5. KING CK, GLASS R, BRESEE JS, DUGGAN C: Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm. Rep. (2003) 52(RR-16):1-16.
6. SANTOSHAM M, KEENAN EM, TULLOCH J, BROUN D, GLASS R: Oral rehydration therapy for diarrhea: an example of reverse transfer of technology. Pediatrics (1997) 100(5):E10.
7. HARTLING L, BELLEMARE S, WIEBE N et al.: Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst. Rev. (Online) (2006) 3:CD004390.
8. GARTHRIGHT WE, ARCHER DL, KVENBERG JE: Estimates of incidence and costs of intestinal infectious diseases in the United States. Public Health Rep. (1988) 103(2):107-115.
9. BLACK RE: Persistent diarrhea in children of developing countries. Pediatr. Infect. Dis. J. (1993) 12(9):751-761; discussion 762-764.
10. ALBANO F, BRUZZESE E, BELLA A et al.: Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur. J. Pediatr. (2007) 166(3):241-247.
11. DE ZOYSA I, FEACHEM RG: Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull. World Health Organ. (1985) 63(3):569-583.
12. VELAZQUEZ FR, MATSON DO, CALVA JJ et al.: Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. (1996) 335(14):1022-1028.
13. VELAZQUEZ FR, MATSON DO, GUERRERO ML et al.: Serum antibody as a marker of proteetion against natural rotavirus infection and disease. J. Infect. Dis. (2000) 182(6):1602-1609.
14. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics. Pediatrics (1998) 102(6):1483-1491.
15. MURPHY TV, GARGIULLO PM, MASSOUDI MS et al.: Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. (2001) 344(8):564-572.
16. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb. Mortal Wkly Rep. (1999) 48(27):577-581.
17. KRAMARZ P, FRANCE EK, DESTEFANO F et al.: Population-based study of rotavirus vaccination and intussusception. Pediatr. Infect. Dis. J. (2001) 20(4):410-416.
18. PETER G, MYERS MG: Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics (2002) 110(6):E67.
19. CENTER FOR DISEASE CONTROL AND PREVENTION (CDC): Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal Wkly Rep. (1999) 48(43):1007.
20. VESIKARI T, KARVONEN A, PUUSTINEN L et al.: Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J. (2004) 23(10):937-943.
21. SALINAS B, PEREZ SCHAEL I, LINHARES AC et al.: Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in latin American infants. Pediatr. Infect. Dis. J. (2005) 24(9):807-816.
22. DE VOS B, VESIKARI T, LINHARES AC et al.: A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. (2004) 23(10 Suppl.):S179-S182.
23. RUIZ-PALACIOS GM, PEREZ-SCHAEL I, VELAZQUEZ FR et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. (2006) 354(1):11-22.
24. CLARK HF, BERNSTEIN DI, DENNEHY PH et al.: Safety, efficacy, and immunogenicity of a live, quadriwalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. (2004) 144(2):184-190.
25. VESIKARI T, CLARK HF, OFFIT PA et al.: The effect of dose and composition of a pentavalent rotavirus vaccine (RotaTeq) upon safety, efficacy, and immunogenicity in healthy infants. Presented at the 22nd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Tampere, Finland (26-28 May 2004).
26. VESIKARI T, MATSON DO, DENNEHY P et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. (2006) 354(1):23-33.
27. LEVINE MM, KAPER JB, HERRINGTON D et al.: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (1988) 2(8609):467-470.
28. KAPERJ B, MICHALSKI J, KETLEY JM, LEVINE MM: Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect. Immun. (1994) 62(4):1480-1483.
29. TACKET CO, COHEN MB, WASSERMAN SS et al.: Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. (1999) 67(12):6341-6345.
30. TACKET CO, LOSONSKY G, NATARO JP et al.: Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. (1992) 166(4):837-841.
31. TAYLOR DN, SANCHEZ JL, CASTRO JM et al.: Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect. Immun. (1999) 67(4):2030-2034.
32. TAYLOR DN, TACKET CO, LOSONSKY G et al.: Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. (1997) 65(9):3852-3856.
33. RICHIE EE, PUNJABI NH, SIDHARTA YY et al.: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 18(22):2399-2410.
34. HOLMGREN J, CZERKINSKY C, LYCKE N, SVENNERHOLM AM: Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am. J. Trop. Med. Hyg. (1994) 50(5 Suppl.):42-54.
35. CLEMENS JD, JERTBORN M, SACK D et al.: Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. J. Infect. Dis. (1986) 154(1):175-178.
36. CLEMENS JD, SACK DA, HARRIS JR et al.: Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 335(8684):270-273.
37. SANCHEZ J, HOLMGREN J: Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development Proc. Natl. Acad. Sci. USA (1989) 86(2):481485.
38. SANCHEZ JL, VASQUEZ B, BEGUE RE et al.: Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 344(8932):1273-1276.
39. TAYLOR DN, CARDENAS V, SANCHEZ JL et al.: Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J. Infect. Dis. (2000) 181(5):1667-1673.
40. PIERCE NF, BANWELL JG, RUPAK DM et al.: Effect of intragastric glucose-electrolyte infusion upon water and electrolyte balance in Asiatic cholera. Gastroenterology (1968) 55(3):333-343.
41. NALIN DR, CASH PA, ISLAM R, MOLLA M, PHILLIPS RA: Oral maintenance therapy for cholera in adults. Lancet (1968) 2(7564):370-373.
42. SCHILLER LR: Review article. anti-diarrhoeal pharmacology and therapeutics. Aliment Pharmacol. Ther. (1995) 9(2):87-106.
43. KIRBY MG, DUKES GE, HEIZER WD, BRYSON JC, POWELL JR: Effect of metoclopramide, bethanechol, and loperamide on gastric residence time, gastric emptying, and mouth-to-cecum transit time. Pharmacotherapy (1989) 9(4):226-231.
44. EL OUFIR L, FLOURIE B, BRULEY DES VARANNES S et al.: Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans. Gut (1996) 38(6):870-877.
45. HUIGHEBAERT S, AWOUTERS F, TYTGAT GN: Racecadotril versus loperamide: antidiarrheal research revisited. Dig. Dis. Sci. (2003) 48(2):239-250.
46. DE LUCA A, COUPAR IM: Insights into opioid action in the intestinal tract. Pharmacol. Ther. (1996) 69(2):103-115.
47. DUVAL-IFLAH Y, BERARD H, BAUMER P et al.: Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet. Aliment Pharmacol. Ther. (1999) 13(Suppl. 6):9-14.
48. KAPLAN MA, PRIOR MJ, MCKONLY KI et al.: A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children. Clin. Pediatr. (Phila.) (1999) 38(10):579-591.
49. MOTALA C, HILL ID, MANN MD, BOWIE MD: Effect of loperamide on stool output and duration of acute infectious diarrhea in infants. J. Pediatr. (1990) 117(3):467-471.
50. OWENS JR, BROADHEAD R, HENDRICKSE RG, JASWAL OP, GANGAL RN: Loperamide in the treatment of acute gastroenteritis in early childhood. Report of a two centre, double-blind, controlled clinical trial. Ann. Trop. Paediatr. (1981) 1(3):135-141.
51. BOWIE MD, HILL ID, MANN MD: Loperamide for treatment of acute diarrhoea in infants and young children. A double-blind placebo-controlled trial. S. Afr. Med. J. (1995) 85(9):885-887.
52. LI ST, GROSSMAN DC, CUMMINGS P: Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med. (2007) 4(3):E98.
53. BHUTTA TI, TAHIR KI: Loperamide poisoning in children. Lancet (1990) 555(8685):363.
54. ERICSSON CD, TANNENBAUM C, CHARLES TT: Antisecretory and antiinflammatory properties of bismuth subsalicylate. Rev. Inject. Dis. (1990) 12(Suppl. 1):S16-S20.
55. DUPONT HL: Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell. Clin. Pharm. (1987) 21(9):687-693.
56. MANHART MD: In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev. Infect. Dis. (1990) 12(Suppl. 1):S11-S15.
57. STEFFEN R: Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea. Rev. Infect. Dis. (1990) 12(Suppl. 1):S80-S86.
58. FIGUEROA-QUINTANILLA D, SALAZAR-LINDO E, SACK RB et al.: A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N. Engl. J. Med. (1993) 328(23):1653-1658.
59. SORIANO-BRUCHER H, AVENDANO P, O'RYAN M et al.: Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics (1991) 87(1):18-27.
60. LEWIS TV, BADILLO R, SCHAEFFER S, HAGEMANN TM, MCGOODWIN L: Salicylate toxicity associated with administration of Percy medicine in an infant. Pharmacotherapy (2006) 26(3):403-409.
61. PICKERING LK, FELDMAN S, ERICSSON CD, CLEARY TG: Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J. Pediatr. (1981) 99(4):654-656.
62. SAINSBURY SJ: Fatal salicylate toxicity from bismuth subsalicylate. West J. Med. (1991) 155(6):637-639.
63. HINTERLEITNER TA, PETRITSCH W, DIMSITY G et al.: Acetorphan prevents cholera-toxin-induced water and electrolyte secretion in the human jejunum. Eur. J. Gastroenterol. Hepatol. (1997) 9(9):887-891.
64. PRIMI MP, BUENO L, BAUMER P, BERARD H, LECOMTE JM: Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 6):3-7.
65. RACHMILEWITZ D, KARMELI F, CHOREV M, SELINGER Z: Effect of opiates on human colonic adenylate cyclase activity. Eur. J. Pharmacol. (1983) 93(3-4):169-173.
66. BERGMANN JF, CHAUSSADE S, COUTURIER D et al.: Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment. Pharmacol. Ther. (1992) 6(3):305-313.
67. SCHWARTZ JC: Racecadotril: a new approach to the treatment of diarrhoea. Int. J. Antimicrob. Agents (2000) 14(1):75-79.
68. SALAZAR-LINDO E, SANTISTEBAN-PONCE J, CHEA-WOO E, GUTIERREZ M: Racecadotril in the treatment of acute watery diarrhea in children. N. Engl. J. Med. (2000) 343(7):463-467.
69. CEZARD JP, DUHAMEL JF, MEYER M et al.: Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology (2001) 120(4):799-805.
70. BHAN MK, BHATNAGAR S: Racecadotril - is there enough evidence to recommend it for treatment of acute diarrhea? Indian Pediatr. (2004) 41(12):1203-1204.
71. BROUILLARD MY, RATEAU JG: Adsorption potency of 2 clays, smectite and kaolin on bacterial enterotoxins. In vitro study in cell culture and in the intestine of newborn mice. Gastroenterol. Clin. Biol. (1989) 13(1):18-24.
72. MAHRAOUI L, HEYMAN M, PLIQUE O, DROY-LEFAIX MT, DESJEUX JF: Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-α Gut (1997) 40(3):339-343.
73. SANDHU BK: Practical guidelines for the management of gastroenteritis in children. J. Pediatr. Gartroenterol. Nutr. (2001) 33(Suppl. 2):S36-S39.
74. SZAJEWSKA H, HOEKSTRA JH, SANDHU B: Management of acute gastroenteritis in Europe and the impact of the new recommendations: a multicenter study. The working group on acute diarrhoea of the European society for paediatric gastroenterology, hepatology, and nutrition. J. Pediatr. Gastroenterol. Nutr. (2000) 30(5):522-527.
75. SZAJEWSKA H, DZIECHCIARZ P, MRUKOWICZ J: Meta-analysis: smectite in the treatment of acute infections diarrhoea in children. Aliment. Pharmacol. Ther. (2006) 23(2):217-227.
76. OZUAH PO, AVNER JR, STEIN RE: Oral rehydration, emergency physicians, and practice parameters: a national survey. Pediatrics (2002) 109(2):259-261.
77. REIS EC, GOEPP JG, KATZ S, SANTOSHAM M: Barriers to use of oral rehydration therapy. Pediatrics (1994) 93(5):708-711.
78. KWON KT, RUDKIN SE, LANGDORF MI: Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians. Clin. Pediatr. (Phila.) (2002) 41(9):641-652.
79. LI ST, DIGIUSEPPE DL, CHRISTAKIS DA: Antiemetic use for acute gastroentetiris in children. Arch. Pediatr. Adolesc. Med. (2003) 157(5):475-479.
80. ALBANO F, BRUZZESE E, SPAGNUOLO MI, DE MARCO G: Antiemetics for children with gastroenteritis: off-label but still on in clinical practice. J. Pediatr. Gastroenterol. Nutr. (2006) 43(3):402-404.
81. BUTCHER ME: Global experience with ondansetron and future potential. Oncology (1993) 50(3):191-197.
82. ROILA F, DEL FAVERO A: Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. (1995) 29(2):95-109.
83. WILDE MI, MARKHAM A: Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs (1996) 52(5):773-794.
84. FRAMARINO DEI MALATESTA M, VENEZIANO M, FIORELLI C et al.: Ondansetron in chemotherapy-induced emesis. Our experience. Eur. J. Gynaecol. Oncol. (1995) 16(2):97-106.
85. SIMPSON KH, HICKS FM: Clinical pharmacokinetics of ondansetron. A review. J. Pharm. Pharmacol. (1996) 48(8):774-781.
86. GARCIA-DEL-MURO X, CARDENAL F, FERRER P: Extrapyramidal reaction associated with ondansetron. Eur. J. Cancer (1993) 29A(2):288.
87. REEVES JJ, SHANNON MW, FLEISHER GR: Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. Pediatrics (2002) 109(4):E62.
88. STORK CM, BROWN KM, REILLY TH, SECRETI L, BROWN LH: Emergency department treatment of viral gastritis ming intravenous ondansetron or dexamethasone in children. Acad. Emerg. Med. (2006) 13(10):1027-1033.
89. RAMSOOK C, SAHAGUN-CARREON I, KOZINETZ CA, MORO-SUTHERLAND D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann. Emerg. Med. (2002) 39 (4):397-403.
90. FREEDMAN SB, ADLER M, SESHADRI R, POWELL EC: Oral ondansetron for gastroenteritis in a pediatric emergency department. N. Engl. J. Med.(2006) 354(16):1698-1705.
91. ROSLUND G, HEPPS T, MCQUILLEN KK: The emergency department role of oral ondansetron in the oral rehydration of children with gastroenteritis-related vomiting. Acad. Emerg. Med. (2006) 13(5 Suppl. 1):S147.
92. ERNST AA, WEISS SJ, PARK S, TAKAKUWA KM, DIERCKS DB: Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. Ann. Emerg. Med. (2000) 36(2):89-94.
93. STARKE PR, WEAVER J, CHOWDHURY BA: Boxed warning added to promethazine labeling for pediatric use. N. Engl. J. Med. (2005) 352(25):2653.
94. BLACK RE, SAZAWAL S: Zinc and childhood infectious disease morbidity and mortality. Br. J. Nutr. (2001) 85(Suppl. 2):S125-S129.
95. HAMBIDGE KM: Zinc and diarrhea. Acta Paediatr. Suppl. (1992) 381:82-86.
96. FRAKER PJ, KING LE, LAAKKO T, VOLLMER TL: The dynamic link between the integrity of the immune system and zinc status. J. Nutr. (2000) 130(5S Suppl.):S1399-S1406.
97. SHANKAR AH, PRASAD AS: Zinc and immune function: the biological basis of altered resistance to infection. Am. J. Clin. Nutr. (1998) 68(2 Suppl.):S447-S463.
98. VALLEE BL, FALCHUK KH: The biochemical basis of zinc physiology. Physiol. Rev. (1993) 73(1):79-118.
99. BHUTTA ZA, BIRD SM, BLACK RE et al.: Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am. J. Clin. Nutr. (2000) 72(6):1516-1522.
100. SAZAWAL S, BLACK RE, BHAN MK et al.: Zinc supplementation in young children with acute diarrhea in India. N. Engl. J. Med. (1995) 333(13):839-844.
101. AL-SONBOLI N, GURGEL RQ, SHENKIN A, HART CA, CUEVAS LE: Zinc supplementation in Brazilian children with acute diarrhoea. Ann. Trop. Paediatr. (2003) 23(1):3-8.
102. DUTTA P, MITRA U, DATTA et al.: Impact of zinc supplementation in malnourished children with acute watery diarrhoea. J. Trop. Pediatr. (2000) 46(5):259-263.
103. BHATNAGAR S, BAHL R, SHARMA PK et al.: Zinc with oral rehydration therapy reduces stool output and duration of diarrhea in hospitalized children: a randomized controlled trial. J. Pediatr. Gastroenterol. Nutr. (2004) 38(1):34-40.
104. FARUQUE AS, MAHALANABIS D, HAQUE SS, FUCHS GJ, HABTE D: Double-blind, randomized, controlled trial of zinc or vitamin A supplementation in young children with acute diarrhoea. Acta Paediatr. (1999) 88(2):154-160.
105. STRAND TA, CHANDYO RK, BAHL R et al.: Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics (2002) 109(5):898-903.
106. BAQUI AH, BLACK RE, ELARIFEEN S et al.: Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial. BMJ (2002) 325(7372):1059.
107. WHO/UNICEF: WHO/UNICEF Joint Statement. Clinical Management of Acute Diarrhoea. The United Nations Children's Fund/World Health Organization (2004).
108. CANANI RB, RUOTOLO S: The dawning of the "zinc era" in the treatment of pediatric acute gastroenteritis worldwide? J. Pediatr. Gastroenterol. Nutr. (2006) 42(3):253-255.
109. BROOKS WA, SANTOSHAM M, ROY SK et al.: Efficacy of zinc in young infants with acute watery diarrhea. Am. J. Clin. Nutr. (2005) 82(3):605-610.
110. FISCHER WALKER CL, BHUTTA ZA, BHANDARI N et al.: Zinc supplementation for the treatment of diarrhea in infants in Pakistan, India and Ethiopia. J. Pediatr. Gastroenterol. Nutr. (2006) 43(3):357-363.
111. KREBS NF: Zinc transfer to the breastfed infant. J. Mammary Gland Biol. Neoplasia (1999) 4(3):259-268.
112. NAIDU AS, BIDLACK WR, CLEMENS RA: Probiotic spectra of lactic acid bacteria (LAB). Crit. Rev. Food Sci. Nutr. (1999) 39(1):13-126.
113. BERNET MF, BRASSART D, NEESER JR, SERVIN AL: Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut (1994) 35(4):483-489.
114. KAILA M, ISOLAURI E, SOPPI E et al.: Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactbacillus strain. Pediatr. Res. (1992) 32(2):141-144.
115. CADIEUX P, BURTON J, GARDINER G et al.: Lactobacillus strains and vaginal ecology. JAMA (2002) 287(15): 1940-1941.
116. KLEIN G, PACKA, BONAPARTE C, REUTER G: Taxonomy and physiology of probiotic lactic acid bacteria. Int. J. Food Microbiol. (1998) 41(2):103-125.
117. ROSENFELDT V, MICHAELSEN KF, JAKOBSEN M et al.: Effect of probiotic Lactobacillus swains on acute diarrhea in a cohort of nonhospitalized children attending day-rare centers. Pediatr. Infect. Dis. J. (2002) 21(5):417-419.
118. GUARINO A, CANANI RB, SPAGNUOLO MI, ALBANO F, DI BENEDETTO L: Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J. Pediatr. Gastroenterol. Nutr. (1997) 25(5):516-519.
119. SZYMANSKI H, PEJCZ J, JAWIEN M et al.: Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains - a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. (2006) 23(2):247-253.
120. ISOLAURI E, JUNTUNEN M, RAUTANEN T, SILLANAUKEE P, KOIVULA T: A human Lactobacillus strain (Lactobacillus casei sp. strain GG) promotes recovery from acute diarrhea in children. Pediatrics (1991) 88(1):90-97.
121. PANT AR, GRAHAM SM, ALLEN SJ et al.: Lactobacillus GG and acute diarrhoea in young children in the tropics. J. Trop. Pediatr. (1996) 42(3):162-165.
122. RAUTANEN T, ISOLAURI E, SALO E, VESIKARI T: Management of acute diarrhoea with low osmolarity oral rehydration solutions and Lactobacillus strain GG. Arch. Dis. Child (1998) 79(2):157-160.
123. SHORNIKOVA AV, ISOLAURI E, BURKANOVA L, LUKOVNIKOVA S, VESIKARI T: A trial in the Karelian republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr. (1997) 86(5):460-465.
124. GUANDALINI S, PENSABENE L, ZIKRI MA et al.: Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J. Pediatr. Gastroenterol. Nutr. (2000) 30(1):54-60.
125. ROSENFELDT V, MICHAELSEN KF, JAKOBSEN M et al.: Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr. Infiet. Dis. J. (2002) 21(5):411-416.
126. SARKER SA, SULTANA S, FUCHS GJ et al.: Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics (2005) 116(2):E221-E228.
127. SZAJEWSKA H, MRUKOWICZ JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J. Pediatr. Gastroenterol. Nutr. (2001) 33(Suppl. 2):S17-S25.
128. VAN NIEL CW, FEUDTNER C, GARRISON MM, CHRISTAKIS DA: Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics (2002) 109(4):678-684.
129. SHORNIKOVA AV, CASAS IA, ISOLAURI E, MYKKANEN H, VESIKARI T: Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J. Pediatr. Gastroenterol. Nutr. (1997) 24(4):399-404.
130. RAZA S, GRAHAM SM, ALLEN SJ et al.: Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr. Infect. Dis. J. (1995) 14(2):107-111.
131. ALLEN SJ, OKOKO B, MARTINEZ E, GREGORIO G, DANS LF: Probiotics for treating infectious diarrhoea. Cochrane Database Syst. Rev. (2004) (2):CD003048.
132. REID G: Safety of Lactobacillus strains as probiotic agents. Clin. Infect. Dis. (2002) 35(3):349-350.
133. BORRIELLO SP, HAMMES WP, HOLZAPFEL W et al.: Safety of probiotics that contain lactobacilli or bifidobacteria. Clin. Infect. Dis. (2003) 36(6):775-780.
134. HUSNI RN, GORDON SM, WASHINGTON JA, LONGWORTH DL: Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin. Infect. Dis. (1997) 25(5):1048-1055.
135. LAND MH, ROUSTER-STEVENS K, WOODS CR et al.: Lactobacillus sepsis associated with probiotic therapy. Pediatrics (2005) 115(1):178-181.
136. REID G, JASS J, SEBULSKY MT, MCCORMICK JK: Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev. (2003) 16(4):658-672.
137. MUNOZ P, BOUZA E, CUENCA-ESTRELLA M et al.: Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin. Infect. Dis. (2005) 40(11):1625-1634.
138. FOX LM, SARAVOLATZ LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. (2005) 40(8):1173-1180.
139. ROSSIGNOL JF, KABIL SM, EL-GOHARY Y, YOUNIS AM: Effect of nitazoxanide in diarrhea and enteritis mused by Cryptosporidium species. Clin. Gastroenterol. Hepatol. (2006) 4(3):320-324.
140. ROSSIGNOL JF, KABIL SM, SAID M, SAMIR H, YOUNIS AM: Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocytis hominis. Clin. Gastroenterol. Hepatol. (2005) 5(10):987-991.
141. MUSHER DM, LOGAN N, HAMILL RJ et al.: Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. (2006) 43(4):421-427.
142. ROSSIGNOL JF, AYOUB A, AYERS MS: Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar - a randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. (2001) 184(3):381-384.
143. ROSSIGNOL JF, KORBA BE, KABIL SM: Nitazoxanide in treating chronic hepatitis B: in vitro activity and clinical case reports. Digestive Disease Week. Los Angeles, CA, USA (20-25 May 2006).
144. ROSSIGNOL JF, KORBA BE, KABIL SM: Nitazoxanide in treating chronic hepatitis C: in vitro activity and clinical case reports. Digestive Disease Week. Los Angeles, CA, USA (20-25 May 2006).
145. ROSSIGNOL JF, ABU-ZEKRY M, HUSSEIN A, SANTORO MG: Effect of nitazoxanlde for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet (2006) 368(9530):124-129.
146. ATHERLY-JOHN YC, CUNNINGHAM SJ, CRAIN EF: A randomizecl trial of oral vs intravenous rehydration in a pediatric emergency department. Arch. Pediatr. Adolesc. Med. (2002) 156(12):1240-1243.
147. NAGER AL, WANG VJ: Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration. Pediatrics (2002) 109(4):566-572.
148. SPANDORFER PR, ALESSANDRINI EA, JOFFE MD, LOCALIO R, SHAW KN: Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial. Pediatrics (2005) 115(2):295-301.
149. SNYDER JD: Use and misuse of oral therapy for diarrhea: comparison of US practices with American Academy of Pediatrics recommendations. Pediatrics (1990 87(1):28-33.
150. DARROW DC, PRATT EL, FLETT JJ, GAMBLE AH, WIESE HF: Disturbances of water and electrolytesin infantile diarrhea. Pediatrics (1949) 3(2):129-156.
151. HOLLIDAY MA, FRIEDMAN AL, WASSNER SJ: Extracellular fluid restoration in dehydration: a critique of rapid versus slow. Pediatr. Nephrol. (1999) 13(4):292-297.
152. HOLLIDAY M: The evolution of therapy for dehydration: should deficit therapy still be taught? Pediatrics (1996) 98(2 Part 1):171-177.
153. SPEROTTO G, CARRAZZA FR, MARCONDES E: Treatment of diarrheal dehydration. Am. J. Clin. Nutr. (1977) 30(9):1447-1456.
154. POSADA G, PIZARRO D: Rehydration by the rapid intravenous route using a solution similar to the one recommended by the World Health Organization for oral rehydration. Bol. Med. Hosp. Infant Mex. (1986) 43(8):463-469.
155. VESIKARI T, ISOLAURI E, BAER M: A comparative trial of rapid oral and intravenous rehydration in acute diarrhoea. Acta Paediatr. Scand. (1987) 76(2):300-305.
156. ROSENSTEIN BJ, BAKER MD: Pediatric outpatient intravenous rehydration. Am. J. Emerg. Med. (1987) 5(3):183-186.
157. RAFIMAN O, BENNISH ML, ALAM AN, SALAM MA: Rapid intravenous rehydration by means of a single polyelectrolyte solution with or without dextrose. J. Pediatr. (1988) 113(4):654-660.
158. MOINEAU G, NEWMAN J: Rapid intravenous rehydration in the pediatric emergency department. Pediatr. Emerg. Care (1990) 6(3):186-188.
159. SUNOTO: Rapid intravenous rehydration in the treatment of acute infantile diarrhoea with severe dehydration. Paediatr. Indones (1990) 30(5-6):154-161.
160. FERRERO FC, OSSORIO MF, VOYER LE et al.: Fast intravenous rehydration with 90 mmol/L of sodium in dehydrated children with diarrhea. Bol. Med. Hosp. Infant Mex. (1991) 48(7):474-478.
161. REID SR, BONADIO WA: Outpatient rapid intravenous rehydration to correct dehydration and resolve vomiting in children with acute gastroenteritis. Ann. Emerg. Med. (1996) 28(3):318-323.
162. NAGER AL, WANG VJ: Comparison of ultra-rapid intravenous hydration and rapid intravenous hydration in pediatric patients with dehydration. Pediatr. Emerg. Care (2004) 20:797 (Abstract).